Johnson & Johnson (UKEX:JNJ) Stock Price, Trades & News

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Financial Strength

7/10

Name	Current	Vs Industry
Cash-To-Debt	0.4
Equity-to-Asset	0.4
Debt-to-Equity	0.68
Debt-to-EBITDA	1.63
Interest Coverage	24.82
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	4.03	Distress Grey Safe
Beneish M-Score	-2.08	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

8/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	8.9
	3-Year EBITDA Growth Rate	19.2
	3-Year EPS without NRI Growth Rate	2.1
	3-Year FCF Growth Rate	7.2
	3-Year Book Growth Rate	4.8
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	9.21
	Future 3-5Y Total Revenue Growth Rate Estimate	7.05

Momentum Rank

3/10

	Name	Current	Vs Industry		Vs History

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.03
	Quick Ratio	0.77
	Cash Ratio	0.38
	Days Inventory	162.44
	Days Sales Outstanding	65.44
	Days Payable	120.28

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Payout Ratio	0.5
	3-Year Dividend Growth Rate	4.9
	3-Year Average Share Buyback Ratio	2.7
	Shareholder Yield %	1.94

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	67.82
	Operating Margin %	26.77
	Net Margin %	21.83
	EBITDA Margin %	34.99
	FCF Margin %	18.07
	OCF Margin %	23.73
	ROE %	26.39
	ROA %	10.73
	ROIC %	14.32
	3-Year ROIIC %	64.04
	ROC (Joel Greenblatt) %	116.4
	ROCE %	18.39
	Years of Profitability over Past 10-Year	10
	Moat Score	9
	Tariff Resilience Score	8

GF Value Rank

5/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	29.8
	Forward PE Ratio	11.47
	PE Ratio without NRI	24.94
	Shiller PE Ratio	32.38
	Price-to-Owner-Earnings	37.48
	PEG Ratio	2.65
	PS Ratio	6.51
	PB Ratio	7.64
	Price-to-Free-Cash-Flow	36.02
	Price-to-Operating-Cash-Flow	27.43
	EV-to-EBIT	25.15
	EV-to-Forward-EBIT	14.03
	EV-to-EBITDA	19.38
	EV-to-Forward-EBITDA	12.26
	EV-to-Revenue	6.78
	EV-to-Forward-Revenue	4.58
	EV-to-FCF	37.53
	Price-to-GF-Value	1.35
	Price-to-Projected-FCF	2.35
	Price-to-DCF (Earnings Based)	1.09
	Price-to-DCF (FCF Based)	1.61
	Price-to-Median-PS-Value	1.35
	Price-to-Peter-Lynch-Fair-Value	2.36
	Earnings Yield (Greenblatt) %	3.98
	FCF Yield %	2.81
	Forward Rate of Return (Yacktman) %	13.28

Financials (Next Earnings Date:2026-07-15)

Annual Quarterly TTM

UKEX:JNJ's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Johnson & Johnson Operating Data

Annual Quarterly

UKEX:JNJ's Complete Operating Data

No operating data available for Johnson & Johnson.

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Johnson & Johnson Executives

Details

GF Value™: ₴4410.94

UKEX:JNJ

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 7 Medium warning signs with JNJ. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil ₴)	4,330,294.16
	EPS (TTM) (₴)	388.712
	Beta	-
	3-Year Sharpe Ratio	-2
	3-Year Sortino Ratio	-1.75
	Volatility %	1.62
	14-Day RSI	-
	14-Day ATR (₴)	-
	20-Day SMA (₴)	5947
	12-1 Month Momentum %	-
	52-Week Range (₴)	5947 - 5947
	Shares Outstanding (Mil)	2,407.22

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	4
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Johnson & Johnson Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Johnson & Johnson Stock Events

Financials Calendars

Event	Date	Price (₴)
Third quarter earnings conference call for 2026	2026-10-13	In 91 days
Third quarter earnings results for 2026	2026-10-13	In 91 days
Second quarter earnings conference call for 2026	2026-07-15 08:30	In 2 days
Second quarter earnings results for 2026	2026-07-15 06:45	In 2 days
Goldman Sachs 47th Annual Global Healthcare Conference	2026-06-09 10:00	5,947.00 (+0.00%)
Bernstein’s 42nd Annual Strategic Decisions Conference	2026-05-27 11:00	5,947.00 (+0.00%)
USD 1.340000 Cash Dividend	2026-05-26	5,947.00 (+0.00%)
Guidance call for 2026	2026-05-19 11:30	5,947.00 (+0.00%)
Guidance call for 2026	2026-05-12 14:20	5,947.00 (+0.00%)
General meeting for 2026	2026-04-23 10:00	5,947.00 (+0.00%)

Show

Entries

Johnson & Johnson Frequently Asked Questions

What is Johnson & Johnson(UKEX:JNJ)'s stock price today?

The current price of UKEX:JNJ is ₴5947.00. The 52 week high of UKEX:JNJ is ₴5947.00 and 52 week low is ₴5947.00.

When is next earnings date of Johnson & Johnson(UKEX:JNJ)?

The next earnings date of Johnson & Johnson(UKEX:JNJ) is 2026-07-15.

Does Johnson & Johnson(UKEX:JNJ) pay dividends? If so, how much?

Johnson & Johnson(UKEX:JNJ) does not pay dividend.

Press Release

	Subject	Date
	Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform	2026-07-08
	Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis	2026-06-26
	Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida	2026-06-15
	New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel	2026-06-13
	Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients	2026-06-11
	IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease wit	2026-06-11
	Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform	2026-06-08
	Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study	2026-06-03
	Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease	2026-06-03
	RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited	2026-05-31

10/Page

Articles on Johnson & Johnson

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.